公司概述
Revolution Medicines, Inc. operates as a clinical-stage precision oncology company dedicated to developing novel targeted therapies specifically designed for RAS-addicted cancers. The company's research and development pipeline focuses on RAS(ON) inhibitors which function by binding to RAS variants, with the intent to utilize these agents as monotherapy or in combination with other RAS(ON) inhibitors. This entity functions within the Healthcare sector and the Biotechnology industry, positioning it as a specialized player in the pursuit of innovative treatments for difficult-to-treat malignancies. With a market capitalization of $19.17B, the company holds a significant valuation relative to its operational scale, which is characterized by a workforce of 883 employees and reported annual revenue of N/A. The substantial market cap figure suggests that the market places a high premium on the company's potential future clinical successes and the proprietary nature of its oncology pipeline, even in the absence of current revenue generation.
财务健康
The company reports a Net Income (TTM) of $-1,131,300,992 and an EBITDA of $-1,174,619,008, while the Revenue (TTM) is listed as N/A, indicating a stage where commercial sales have not yet materialized. The significant gap between revenue (which is effectively zero in this reporting period) and the massive net loss reveals a cost structure heavily weighted toward research, development, and clinical trial expenses typical of a clinical-stage biotechnology firm. Free Cash Flow stands at $-523,279,008, which indicates that the company is burning cash at a rapid pace to fund its operations and pipeline advancement. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, reflecting that the company has not yet achieved commercial profitability or generated measurable sales revenue to calculate margins. Despite the negative earnings, the company holds $2.03B in cash against $427.15M in debt, resulting in a Debt to Equity ratio of 26.18, which suggests a balance sheet that is currently funded primarily by equity and cash reserves rather than leverage. The Current Ratio is 7.14, indicating a very strong short-term liquidity position where current assets significantly exceed current liabilities, providing ample buffer for operational needs. Return on Equity is -58.1% and Return on Assets is -30.1%, metrics that reveal management is currently deploying capital to generate losses rather than returns, a standard characteristic for clinical-stage biotech firms awaiting product approval.
估值评估
The Trailing P/E Ratio (TTM) is N/A due to the negative net income, while the Forward P/E is -14.36, a negative figure that implies the market is pricing the stock based on future expectations rather than current earnings performance. The Price to Book ratio stands at 11.68, indicating that the market values the company at a significant premium over its tangible book value, likely reflecting the high value placed on its intellectual property and pipeline potential. The Price to Sales ratio is N/A and the EV/EBITDA is -14.96, suggesting that traditional valuation multiples based on profitability or sales efficiency are not currently applicable to this clinical-stage entity. The 52-week high is $124.49 and the 52-week low is $29.98, meaning the stock price has experienced extreme volatility within this trading range over the past year. The Beta is 1.01, which indicates that the stock's price volatility is virtually identical to the broader market, moving in tandem with general market fluctuations rather than exhibiting significantly higher or lower systemic risk.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, as the company has not yet generated consistent commercial revenue streams to calculate year-over-year growth rates. Consequently, there is no data to compare earnings growth against revenue growth, but the absence of such figures underscores the company's focus on R&D investment rather than top-line expansion. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which means the company reinvests all available capital and earnings back into its research pipeline and clinical trials rather than distributing income to shareholders. This growth and income profile characterizes Revolution Medicines as a capital-intensive asset that relies entirely on future clinical milestones and regulatory approvals to transition from a cash-burning clinical-stage company to a profitable commercial entity.